Loading…
ASPP1/2 positive patients with invasive breast cancers have good prognosis
Although the expression of ASPP family members in multiple tumors has been studied, especially in various cell lines of breast cancer (BC), but the expressions pattern of ASPP family members in invasive BC tissues are not clear. We studied the expression and expression pattern of ASPPs family member...
Saved in:
Published in: | Heliyon 2023-10, Vol.9 (10), p.e20613-e20613, Article e20613 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c492t-93ef1030cdfa6ce11420087d762ea826561c154a3386992d86ec0b5a87c124ac3 |
container_end_page | e20613 |
container_issue | 10 |
container_start_page | e20613 |
container_title | Heliyon |
container_volume | 9 |
creator | Wang, Changsong Li, Ke An, Junling Lv, Xuexia Ma, Wenfeng Wang, Yaxi Meng, Nianlong Yun, Tian Zhao, Ting |
description | Although the expression of ASPP family members in multiple tumors has been studied, especially in various cell lines of breast cancer (BC), but the expressions pattern of ASPP family members in invasive BC tissues are not clear. We studied the expression and expression pattern of ASPPs family member in BCs, the relationship between ASPP family members and clinic-pathologic features of BCs was also analyzed. The results showed that the expression of ASPP1, ASPP2 and iASPP was observed on AE1/AE3+ tumor cells, and not on infiltrated lymphocytes and capillaries. The relationship between ASPP1 expression and pTNM stage has statistical difference (p<0.01). The relationship between expression of ASPP2 and SBR grade has statistical difference (p<0.05). The relationship between expression of iASPP and clinic-pathologic feature of patients has no statistical difference (p>0.05). The patients with positive expression of ASPP1 and the patients with negative expression of ASPP1 have statistical difference in 3-year survival rate and 5-year survival rate (χ2 = 4.49, P = 0.03; χ2 = 3.79, P = 0.048). Overall, our work demonstrated that the expression of ASPP1/2 contributes to predict the prognosis of patients with BC. |
doi_str_mv | 10.1016/j.heliyon.2023.e20613 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_effaeb55e7164aa18a313e5364445454</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2405844023078210</els_id><doaj_id>oai_doaj_org_article_effaeb55e7164aa18a313e5364445454</doaj_id><sourcerecordid>2883573061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-93ef1030cdfa6ce11420087d762ea826561c154a3386992d86ec0b5a87c124ac3</originalsourceid><addsrcrecordid>eNqFkU1rGzEQhkVpocHJTyjssRc7Gn2t9lRC6EdKoIG2ZzHWztoy69VWWrvk31dbmzY5BR0kXo0eZvQw9g74CjiY691qS314jMNKcCFXJLgB-YpdCMX10irFXz85v2VXOe8456CtaWp5wb7efH94gGtRjTGHKRypGnEKNEy5-h2mbRWGI-Y5XifCPFUeB08pV1ss2SbGthpT3Azlcb5kbzrsM12d9wX7-enjj9svy_tvn-9ub-6XXjViWjaSOuCS-7ZD4wlACc5t3dZGEFphtAEPWqGUpcVGtNaQ52uNtvYgFHq5YHcnbhtx58YU9pgeXcTg_gYxbRymKfieHHUd0lprqsEoRLAoQZKWRimlyyqsDyfWeFjvqfVl8IT9M-jzmyFs3SYeHXDd1BZmwvszIcVfB8qT24fsqe9xoHjIToKWtZJg6xdLhbVS13IWuGD6VOpTzDlR968l4G727nbu7N3N3t3J-_95qAg4Bkou-2LTUxsS-an8UHiB8AdTxbih</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2883573061</pqid></control><display><type>article</type><title>ASPP1/2 positive patients with invasive breast cancers have good prognosis</title><source>ScienceDirect</source><source>PubMed (Medline)</source><creator>Wang, Changsong ; Li, Ke ; An, Junling ; Lv, Xuexia ; Ma, Wenfeng ; Wang, Yaxi ; Meng, Nianlong ; Yun, Tian ; Zhao, Ting</creator><creatorcontrib>Wang, Changsong ; Li, Ke ; An, Junling ; Lv, Xuexia ; Ma, Wenfeng ; Wang, Yaxi ; Meng, Nianlong ; Yun, Tian ; Zhao, Ting</creatorcontrib><description>Although the expression of ASPP family members in multiple tumors has been studied, especially in various cell lines of breast cancer (BC), but the expressions pattern of ASPP family members in invasive BC tissues are not clear. We studied the expression and expression pattern of ASPPs family member in BCs, the relationship between ASPP family members and clinic-pathologic features of BCs was also analyzed. The results showed that the expression of ASPP1, ASPP2 and iASPP was observed on AE1/AE3+ tumor cells, and not on infiltrated lymphocytes and capillaries. The relationship between ASPP1 expression and pTNM stage has statistical difference (p<0.01). The relationship between expression of ASPP2 and SBR grade has statistical difference (p<0.05). The relationship between expression of iASPP and clinic-pathologic feature of patients has no statistical difference (p>0.05). The patients with positive expression of ASPP1 and the patients with negative expression of ASPP1 have statistical difference in 3-year survival rate and 5-year survival rate (χ2 = 4.49, P = 0.03; χ2 = 3.79, P = 0.048). Overall, our work demonstrated that the expression of ASPP1/2 contributes to predict the prognosis of patients with BC.</description><identifier>ISSN: 2405-8440</identifier><identifier>EISSN: 2405-8440</identifier><identifier>DOI: 10.1016/j.heliyon.2023.e20613</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><subject>breast neoplasms ; breasts ; family ; prognosis ; survival rate</subject><ispartof>Heliyon, 2023-10, Vol.9 (10), p.e20613-e20613, Article e20613</ispartof><rights>2023 The Authors</rights><rights>2023 The Authors 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c492t-93ef1030cdfa6ce11420087d762ea826561c154a3386992d86ec0b5a87c124ac3</cites><orcidid>0000-0001-5686-7912</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597814/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2405844023078210$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,3536,27903,27904,45759,53769,53771</link.rule.ids></links><search><creatorcontrib>Wang, Changsong</creatorcontrib><creatorcontrib>Li, Ke</creatorcontrib><creatorcontrib>An, Junling</creatorcontrib><creatorcontrib>Lv, Xuexia</creatorcontrib><creatorcontrib>Ma, Wenfeng</creatorcontrib><creatorcontrib>Wang, Yaxi</creatorcontrib><creatorcontrib>Meng, Nianlong</creatorcontrib><creatorcontrib>Yun, Tian</creatorcontrib><creatorcontrib>Zhao, Ting</creatorcontrib><title>ASPP1/2 positive patients with invasive breast cancers have good prognosis</title><title>Heliyon</title><description>Although the expression of ASPP family members in multiple tumors has been studied, especially in various cell lines of breast cancer (BC), but the expressions pattern of ASPP family members in invasive BC tissues are not clear. We studied the expression and expression pattern of ASPPs family member in BCs, the relationship between ASPP family members and clinic-pathologic features of BCs was also analyzed. The results showed that the expression of ASPP1, ASPP2 and iASPP was observed on AE1/AE3+ tumor cells, and not on infiltrated lymphocytes and capillaries. The relationship between ASPP1 expression and pTNM stage has statistical difference (p<0.01). The relationship between expression of ASPP2 and SBR grade has statistical difference (p<0.05). The relationship between expression of iASPP and clinic-pathologic feature of patients has no statistical difference (p>0.05). The patients with positive expression of ASPP1 and the patients with negative expression of ASPP1 have statistical difference in 3-year survival rate and 5-year survival rate (χ2 = 4.49, P = 0.03; χ2 = 3.79, P = 0.048). Overall, our work demonstrated that the expression of ASPP1/2 contributes to predict the prognosis of patients with BC.</description><subject>breast neoplasms</subject><subject>breasts</subject><subject>family</subject><subject>prognosis</subject><subject>survival rate</subject><issn>2405-8440</issn><issn>2405-8440</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqFkU1rGzEQhkVpocHJTyjssRc7Gn2t9lRC6EdKoIG2ZzHWztoy69VWWrvk31dbmzY5BR0kXo0eZvQw9g74CjiY691qS314jMNKcCFXJLgB-YpdCMX10irFXz85v2VXOe8456CtaWp5wb7efH94gGtRjTGHKRypGnEKNEy5-h2mbRWGI-Y5XifCPFUeB08pV1ss2SbGthpT3Azlcb5kbzrsM12d9wX7-enjj9svy_tvn-9ub-6XXjViWjaSOuCS-7ZD4wlACc5t3dZGEFphtAEPWqGUpcVGtNaQ52uNtvYgFHq5YHcnbhtx58YU9pgeXcTg_gYxbRymKfieHHUd0lprqsEoRLAoQZKWRimlyyqsDyfWeFjvqfVl8IT9M-jzmyFs3SYeHXDd1BZmwvszIcVfB8qT24fsqe9xoHjIToKWtZJg6xdLhbVS13IWuGD6VOpTzDlR968l4G727nbu7N3N3t3J-_95qAg4Bkou-2LTUxsS-an8UHiB8AdTxbih</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Wang, Changsong</creator><creator>Li, Ke</creator><creator>An, Junling</creator><creator>Lv, Xuexia</creator><creator>Ma, Wenfeng</creator><creator>Wang, Yaxi</creator><creator>Meng, Nianlong</creator><creator>Yun, Tian</creator><creator>Zhao, Ting</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5686-7912</orcidid></search><sort><creationdate>20231001</creationdate><title>ASPP1/2 positive patients with invasive breast cancers have good prognosis</title><author>Wang, Changsong ; Li, Ke ; An, Junling ; Lv, Xuexia ; Ma, Wenfeng ; Wang, Yaxi ; Meng, Nianlong ; Yun, Tian ; Zhao, Ting</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-93ef1030cdfa6ce11420087d762ea826561c154a3386992d86ec0b5a87c124ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>breast neoplasms</topic><topic>breasts</topic><topic>family</topic><topic>prognosis</topic><topic>survival rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Changsong</creatorcontrib><creatorcontrib>Li, Ke</creatorcontrib><creatorcontrib>An, Junling</creatorcontrib><creatorcontrib>Lv, Xuexia</creatorcontrib><creatorcontrib>Ma, Wenfeng</creatorcontrib><creatorcontrib>Wang, Yaxi</creatorcontrib><creatorcontrib>Meng, Nianlong</creatorcontrib><creatorcontrib>Yun, Tian</creatorcontrib><creatorcontrib>Zhao, Ting</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ: Directory of Open Access Journals</collection><jtitle>Heliyon</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Changsong</au><au>Li, Ke</au><au>An, Junling</au><au>Lv, Xuexia</au><au>Ma, Wenfeng</au><au>Wang, Yaxi</au><au>Meng, Nianlong</au><au>Yun, Tian</au><au>Zhao, Ting</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ASPP1/2 positive patients with invasive breast cancers have good prognosis</atitle><jtitle>Heliyon</jtitle><date>2023-10-01</date><risdate>2023</risdate><volume>9</volume><issue>10</issue><spage>e20613</spage><epage>e20613</epage><pages>e20613-e20613</pages><artnum>e20613</artnum><issn>2405-8440</issn><eissn>2405-8440</eissn><abstract>Although the expression of ASPP family members in multiple tumors has been studied, especially in various cell lines of breast cancer (BC), but the expressions pattern of ASPP family members in invasive BC tissues are not clear. We studied the expression and expression pattern of ASPPs family member in BCs, the relationship between ASPP family members and clinic-pathologic features of BCs was also analyzed. The results showed that the expression of ASPP1, ASPP2 and iASPP was observed on AE1/AE3+ tumor cells, and not on infiltrated lymphocytes and capillaries. The relationship between ASPP1 expression and pTNM stage has statistical difference (p<0.01). The relationship between expression of ASPP2 and SBR grade has statistical difference (p<0.05). The relationship between expression of iASPP and clinic-pathologic feature of patients has no statistical difference (p>0.05). The patients with positive expression of ASPP1 and the patients with negative expression of ASPP1 have statistical difference in 3-year survival rate and 5-year survival rate (χ2 = 4.49, P = 0.03; χ2 = 3.79, P = 0.048). Overall, our work demonstrated that the expression of ASPP1/2 contributes to predict the prognosis of patients with BC.</abstract><pub>Elsevier Ltd</pub><doi>10.1016/j.heliyon.2023.e20613</doi><orcidid>https://orcid.org/0000-0001-5686-7912</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2405-8440 |
ispartof | Heliyon, 2023-10, Vol.9 (10), p.e20613-e20613, Article e20613 |
issn | 2405-8440 2405-8440 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_effaeb55e7164aa18a313e5364445454 |
source | ScienceDirect; PubMed (Medline) |
subjects | breast neoplasms breasts family prognosis survival rate |
title | ASPP1/2 positive patients with invasive breast cancers have good prognosis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T02%3A46%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ASPP1/2%20positive%20patients%20with%20invasive%20breast%20cancers%20have%20good%20prognosis&rft.jtitle=Heliyon&rft.au=Wang,%20Changsong&rft.date=2023-10-01&rft.volume=9&rft.issue=10&rft.spage=e20613&rft.epage=e20613&rft.pages=e20613-e20613&rft.artnum=e20613&rft.issn=2405-8440&rft.eissn=2405-8440&rft_id=info:doi/10.1016/j.heliyon.2023.e20613&rft_dat=%3Cproquest_doaj_%3E2883573061%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c492t-93ef1030cdfa6ce11420087d762ea826561c154a3386992d86ec0b5a87c124ac3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2883573061&rft_id=info:pmid/&rfr_iscdi=true |